School of Medicine


Showing 821-830 of 856 Results

  • Virginia Winn

    Virginia Winn

    Associate Professor of Obstetrics and Gynecology (Reproductive and Stem Cell Biology)

    Current Research and Scholarly InterestsThe Winn Laboratory seeks to understand the unique aspects of human placental biology that contribute to pregnancy complications. Abnormalities in placental biology lead to more than 25% of pregnancy complications that impact the health of mothers and their babies. The primary focus of Dr. Winn's lab is to understand human placentation and preeclampsia pathogenesis. Both basic science and translational approaches are undertaken.

  • Terry Winograd

    Terry Winograd

    Professor of Computer Science, Emeritus

    BioProfessor Winograd's focus is on human-computer interaction design and the design of technologies for development. He directs the teaching programs and HCI research in the Stanford Human-Computer Interaction Group, which recently celebrated it's 20th anniversary. He is also a founding faculty member of the Hasso Plattner Institute of Design at Stanford (the "d.school") and on the faculty of the Center on Democracy, Development, and the Rule of Law (CDDRL)

    Winograd was a founding member and past president of Computer Professionals for Social Responsibility. He is on a number of journal editorial boards, including Human Computer Interaction, ACM Transactions on Computer Human Interaction, and Informatica. He has advised a number of companies started by his students, including Google. In 2011 he received the ACM SIGCHI Lifetime Research Award.

  • Wing Hung Wong

    Wing Hung Wong

    Stephen R. Pierce Family Goldman Sachs Professor of Science and Human Health and Professor of Biomedical Data Science
    On Leave from 10/01/2021 To 12/31/2021

    Current Research and Scholarly InterestsCurrent interest centers on the application of statistics to biology and medicine. We are particularly interested in questions concerning gene regulation, genome interpretation and their applications to precision medicine.

  • Edward H. Wood, MD

    Edward H. Wood, MD

    Assistant Professor of Ophthalmology

    Current Research and Scholarly Interestshttp://med.stanford.edu/woodlab.html

    Edward H. Wood, MD is an assistant professor of ophthalmology practicing adult and pediatric vitreoretinal surgery at Stanford University School of Medicine. Dr. Wood engages in translational research with the goal of developing new therapies and approaches for patients without viable treatment options. He does so through leveraging the technologies of patient derived stem cells, optogenetics, and phenotypic drug screening in conjunction with active clinical research and surgical device development. Dr. Wood has filed numerous patents and founded several healthcare startups with the goal of improving patients’ quality of life. His research interests include regenerative medicine, drug discovery, and pediatric retinal disease with the ultimate goal of pursuing basic science discoveries with potential for impactful clinical translation. His research interests are significantly inspired by his patients, and he is driven towards not only delivering the highest quality of care currently available, but also in developing the future standard of care in the field of medical retina and vitreoretinal surgery.

  • Mollie Woodworth

    Mollie Woodworth

    Instructor, Ophthalmology

    Current Research and Scholarly InterestsMany types of blindness result from the neurons of the retina no longer being able to communicate with the brain due to injury or disease. In mammals, the adult retina cannot make new retinal ganglion cells (the neurons that connect the retina with the brain) to replace those that are lost. In my work, I aim to learn about normal development of retinal ganglion cells and, further, to regenerate new retinal ganglion cells if they are lost in adulthood.

  • John Fraser Wright

    John Fraser Wright

    Professor (Research) of Pediatrics (Stem Cell Transplantation)

    BioJ Fraser Wright, PhD
    Dr. Wright received his PhD in 1989 from the University of Toronto (Biochemistry) for studies
    characterizing the interaction of complement with IgM, and completed post-doctoral studies at INSERM
    / CENG Grenoble, France in molecular immunology focused on antigen processing and presentation. He
    was awarded a CRCS/ MRC Scholarship, gaining faculty appointment at the University of Toronto. In
    1996 he joined industry as a Scientist at Pasteur Sanofi, contributing there to the development of
    vaccines and cancer immunotherapies, and subsequently as Director of Development and Clinical
    Manufacturing at Avigen, a gene therapy company that pioneered AAV-based investigational gene
    therapies for hemophilia and Parkinson’s disease. In 2004 he returned to academia, establishing and
    directing the Clinical Vector Facility at the Center for Cellular and Molecular Therapeutics at Children’s
    Hospital of Philadelphia, and gaining faculty appointment at the University of Pennsylvania Perelman
    School of Medicine as professor of Pathology and Laboratory Medicine. Dr. Wright has contributed to
    several clinical development programs in gene therapy, including for Luxturna and Kymriah, the first
    gene therapies for a genetic (RPE65 deficiency) and non-genetic (CAR-T immunotherapy) disease,
    respectively, approved in the United States, and for the first gene therapy clinical trial that delivered an
    AAV-vectorized monoclonal antibody to human subjects for HIV passive immunity. He is a Co-founder of
    Spark Therapeutics, serving there and subsequently at Axovant as Chief Technology Officer. In 2019 Dr.
    Wright joined Stanford University as Professor of Pediatrics at The Center for Definitive and Curative
    Medicine (CDCM). His research program aims to address key immunological barriers to gene therapy
    through innovative approaches to viral vector design and generation, and to develop vectorized
    antibodies for serious human diseases.

  • Albert Y. Wu, MD, PhD, FACS

    Albert Y. Wu, MD, PhD, FACS

    Assistant Professor of Ophthalmology

    Current Research and Scholarly InterestsMy translational research focuses on using autologous stem cells to recreate a patient’s ocular tissues for potential transplantation. We are generating tissue from induced pluripotent stem cells to treat limbal stem cell deficiency in patients who are bilaterally blind. By applying my background in molecular and cellular biology, stem cell biology, oculoplastic surgery, I hope to make regenerative medicine a reality for those suffering from orbital and ocular disease.

  • Chien-Ting Wu

    Chien-Ting Wu

    Postdoctoral Scholar, Microbiology and Immunology

    BioI started conducting research as a second-year student in college. I entered a biochemical lab to perform research and had my own project. My topic was Alzheimer's disease, and I focused on the relationship between aggregated amyloid-beta and reactive oxygen species levels in cells. I am very grateful for this particular research experience because it allowed me to realize that I am particularly interested in studying disease-associated proteins on a molecular level. Thus, these early research experiences have been invaluable in shaping my scientific interests and personality.

    I decided to pursue my graduate training straight out of college by obtaining my master’s degree. I then decided to join the Chen, I-T. Lab for my graduate research training, where I discovered that a novel recombinant protein, LZ8 cloned from Ganoderma, can inhibit the duplication of cancer cells in vitro and decrease the growth rate of tumors in vivo through regulating the p53/MDM2/mTOR signaling pathway. My findings were published in the journal Carcinogenesis. This was my first first-author paper. During this time, I learned how to become an independent scientist.

    After my master’s degree, I spent three years completing my military service as a research assistant in Academia Sinica. I worked under the supervision of Prof. Tang Tang. My research focused on the molecular mechanism of centriole duplication. In my research, I found that CEP120, a ciliopathy protein, is required to promote centriole elongation. Overexpression of CEP120 can induce overly long centrioles. This work was published in the Journal of Cell Biology. This was my second first-author paper. Because of these valuable lab experiences, I began to be fascinated by the centriole and cilium field.

    Afterwards, to better understand centriole- and cilia-related human hereditary diseases, I worked as a molecular diagnostician in a molecular diagnosis lab at Oregon Health Science University. I used next-generation sequencing (NGS) to identify gene mutations from ciliopathy patients. During this period, I learned how to run a complete molecular diagnosis, draw blood for running NGS, analyzing patient data, preparing patient reports and designing a novel disease panel to run NGS. This experience provided me with a new perspective and connected the things that I learned in the centriole and cilia field, from biochemistry to molecular biology to clinical diagnosis. Most importantly, this experience allowed me to realize that so many people suffer from ciliopathy disease.

    I am currently a Postdoctoral Scholar with Dr. Peter Jackson in the Department of Microbiology and Immunology at Stanford University and collaborate with Dr. Raul Andino in the Department of Microbiology and Immunology at University of California, San Francisco. I study the molecular mechanism of respiratory virus infections, including respiratory syncytial virus (RSV), parainfluenza virus (PIV), and SARS-CoV-2, in the human airway epithelium using cell biological and proteomics approaches to identify potential targets for antiviral drug development.

  • Hsi-Yang Wu

    Hsi-Yang Wu

    Current Research and Scholarly InterestsI am interested in how the brain matures to control the bladder and external sphincter to achieve urinary continence. Using functional MRI of the brain, we are investigating if certain patterns of activity will predict which children will respond to therapy for incontinence.